{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062937","form_type":"8-K","ticker":"DSGN","cik":"0001807120","company_name":"Design Therapeutics, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.559755+00:00","generated_at":"2026-06-08T05:21:23.015420+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Design Therapeutics reports Q3 net loss of $15.8M, extends cash runway to 5 years, appoints Pratik Shah as CEO","bullets":["Net loss of $15.8M for Q3 2023; R&D expenses $13.3M, G&A expenses $5.6M.","Cash and securities of $290.9M as of Sep 30, 2023, expected to fund operations through at least 2028.","Strategic realignment initiated to prioritize long-term growth, focus capital, and implement cost savings.","Pratik Shah appointed as Chief Executive Officer, leading company turnaround and portfolio review.","Comprehensive corporate and pipeline update planned for early 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062937","json":"https://secwatch.observer/filing/0000950170-23-062937.json","markdown":"https://secwatch.observer/filing/0000950170-23-062937.md","text":"https://secwatch.observer/filing/0000950170-23-062937.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807120/000095017023062937/0000950170-23-062937-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807120/000095017023062937/dsgn-20231113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:21:23.015420+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b50251a1dd764fdba98eadf166c9f64799bdbd4c","claim":"Design Therapeutics, Inc. reported third quarter 2023 results: net income Net loss was $15.8 million for the quarter ended September 30, 2023.. Guidance reaffirmed.","evidence_excerpt":"Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today reported third quarter 2023 financial results.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1807120/000095017023062937/0000950170-23-062937-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter 2023"},{"label":"Net income","value":"Net loss was $15.8 million for the quarter ended September 30, 2023."},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}